Igm Biosciences Inc. (IGMS)
NASDAQ (NGS) NASDAQ (NGS) Primary 
IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of a loss of $0.3 per share. This compares to a loss of $0.79 per share a year ago.
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.83 per share a year ago.
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround
IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
IGM Biosciences downgraded to Hold from Buy at Stifel
Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmune and inflammatory disease applications for the downgrade. The strategic pivot will trigger the evaluation of both internal and external/ alternatives and an over 70% workforce reduction, the analyst tells investors in a research note.
IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune programs, a 73% workforce reduction and plans to evaluate strategic alternatives, the analyst tells investors in a research note. The firm cites near-term uncertainty related to the future of IGM for the downgrade.
IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2, down from $21, following the company's strategic update, which included discontinuation of imvotamab and IGM-2644 in autoimmune diseases. Management noted data from Phase 1b studies evaluating imvotamab in patients with rheumatoid arthritis and systemic lupus erythematosus showed insufficient B cell depletion, the analyst tells investors in a research note. BMO says the update was surprising based on the mechanistic rationale of the TCE-CD20 approach "but speaks to the unpredictability" of T cell mediated approaches in cancer and autoimmune disease. It sees the stock trading at IGM's cash following the update.
IGM Biosciences, Inc. (IGMS) Reports Q3 Loss, Tops Revenue Estimates
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago.
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
All You Need to Know About IGM Biosciences (IGMS) Rating Upgrade to Buy
IGM Biosciences (IGMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates
IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $1.43 per share a year ago.
IGM Biosciences (IGMS) Soars 32.7%: Is Further Upside Left in the Stock?
IGM Biosciences (IGMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
